TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'

Benzinga Logo Benzinga By Vandana Singh
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'

Novo Nordisk made an unsolicited $9 billion acquisition proposal for Metsera at $77.75 per share, challenging Pfizer's existing $4.9 billion agreement to acquire the company. Pfizer strongly criticized the proposal as 'reckless' and potentially anti-competitive.

Insights
WFCpA   neutral

Mentioned as an example of a common stock, with no specific analysis provided


MTSR   neutral

Company is the target of competing acquisition proposals